Status:
UNKNOWN
The Long-term Effect of SAAE and Medical Treatment for Primary Aldosteronism
Lead Sponsor:
First Affiliated Hospital of Chengdu Medical College
Conditions:
Primary Aldosteronism
Eligibility:
All Genders
18-75 years
Brief Summary
In this prospective controlled trial, we aim to determine whether superselective adrenal artery embolization is superior to medical treatment for patients with PA who refuse surgery for medication. Pa...
Detailed Description
Primary aldosteronism (PA) is the main cause of secondary hypertension, affecting 5%-15% of the general hypertensive population. Early diagnosis and treatment are of crucial importance because patient...
Eligibility Criteria
Inclusion
- Clinical diagnosis of PA
- They refused medication treatment due to intolerance of side effects
- They had lateralization by adrenal venous sampling (AVS), and refused the adrenalectomy
Exclusion
- History of serious contrast agent allergy
- Complication with severe liver diseases
- History of myocardial infarction and stent implantation within the past 3 months
- Renal insufficiency, with serum creatinine \>176 umo/L
- Pregnancy or lactation
- History of participation in another clinical trial in the past 3 months
- Any serious comorbidity
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT05262660
Start Date
April 1 2022
End Date
January 1 2025
Last Update
March 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yaqiong Zhou
Chengdu, Sichuan, China, 610500